Estimation of plasma IC50 of donepezil hydrochloride for brain acetylcholinesterase inhibition in monkey using N-[11C] methylpiperidin-4-yl acetate ([11C]MP4A) and PET

Neuropsychopharmacology

Volumn 30, Issue 12, 2005, Pages 2154-2161

  Shiraishi, Tetsuya ^a   Kikuchi, Tatsuya ^a   Fukushi, Kiyoshi ^a   Shinotoh, Hitoshi ^a,b   Nagatsuka, Shin Ichiro ^a,c   Tanaka, Noriko ^a,d   Ota, Tsuneyoshi ^a,e   Sato, Koichi ^a   Hirano, Shigeki ^a   Tanada, Shuji ^a   Iyo, Masaomi ^a   Irie, Toshiaki ^a,f  

^a CHIBA UNIVERSITY   (Japan)

^b Asahi Neurological Hospital   (Japan)

^c ADME/TOX Research Institute   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e JUNTENDO UNIVERSITY   (Japan)

^f NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Donepezil hydrochloride; In vivo IC50; N 11C methylpiperidin 4 yl acetate ( 11C MP4A); Positron emission tomography (PET)

Indexed keywords

ACETIC ACID DERIVATIVE; ACETYLCHOLINESTERASE; BRAIN ENZYME; CARBON 11; CHOLINESTERASE INHIBITOR; DONEPEZIL; N METHYLPIPERIDIN 4 YLACETATE; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; INDAN DERIVATIVE; N METHYLPIPERIDIN 4 YL ACETATE; N-METHYLPIPERIDIN-4-YL ACETATE; PIPERIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; IN VIVO STUDY; MALE; NEOCORTEX; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; ALGORITHM; ANIMAL; BLOOD; BRAIN; BRAIN CORTEX; DRUG EFFECT; ENZYMOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MACACA; METABOLISM;

ACETYLCHOLINESTERASE; ALGORITHMS; ANIMALS; BRAIN; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; INDANS; INJECTIONS, INTRAVENOUS; MACACA MULATTA; MALE; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 27844499734     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300759     Document Type: Article

References (28)

1. Bartus RT, Dean III RL, Beer B, Lippa AS (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408-414.
2. Carson RE (1986). Parameter estimation in positron emission tomography. In: Phelps M, Mazziotta J, Schelbert H (eds). Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart. Raven Press: New York. pp 347-390.
3. Dawson RM (1990). Reversibility of the inhibition of acetylcholinesterase by tacrine. Neurosci Lett 118: 85-87.
4. 11C]donepezil as a tracer for visualization of acetylcholinesterase by PET. Nucl Med Biol 27: 745-747.
5. Hunter AJ, Murray TK, Jones JA, Cross AJ, Green AR (1989). The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro. Br J Pharmacol 98: 79-86.
6. Irie T, Fukushi K, Akimoto Y, Tamagami H, Nozaki T (1994). Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AchE) in vivo. Nucl Med Biol 21: 801-808.
7. Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, Sudo T, Suzuki K, Irie T (1997). Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 349: 1805-1809.
8. Kaasinen V, Nagren K, Jarvenpaa T, Roivainen A, Yu M, Oikonen V (2002). Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol 22: 615-620.
9. Kaufer D, Friedman A, Seidman S, Soreq H (1998). Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 393: 373-377.
10. Kawashima K, Sato A, Yoshizawa M, Fujii T, Fujimoto K, Suzuki T (1994). Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn-Schmiedebergs Arch Pharmacol 350: 523-528.
11. 11C]PMP). Synapse 22: 123-131.
12. 11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography trace for measurement of acetylcholinesterase activity in human brain. J Cereb Blood Flow Metab 19: 1150-1163.
13. Kosasa T, Kuriya Y, Matsui K, Yamanishi Y (2000). Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats. Eur J Pharmacol 389: 173-179.
14. Kosasa T, Kuriya Y, Yamanishi Y (1999). Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats. Jpn J Pharmacol 81: 216-222.
15. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL et al (1999). In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 52: 691-699.
16. Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA (2000). Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 48: 391-395.
17. Mihara M, Ohnishi A, Tomono Y, Hasegawa J, Shimamura Y, Yamazaki K et al (1993). Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 31: 223-229.
18. Namba H, Iyo M, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T et al (1999). Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age. Eur J Nucl Med 26: 135-143.
19. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y (2000). Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol 22: 609-613.
20. 11C]methylspiperone binding in vivo: positron emission tomography study using conscious rhesus monkey. Brain Res 663: 191-198.
21. Reiner E, Radic Z (2000). Mechanism of action of cholinesterase inhibitors. In: Giacobini E (ed). Cholinesterases and cholinesterase inhibitors. Martin Dunitz: London. pp 103-119.
22. Rho JP, Lipson LG (1997). Focus on donepezil: a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Formulary 32: 677-678.
23. Rogers SL, Doody RS, Mohs RC, Friedhoff LT (1998). Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 158: 1021-1031.
24. Shinotoh H, Aotsuka A, Fukushi K, Nagatsuka S, Tanaka N, Ota T et al (2001). Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 56: 408-410.
25. Tiseo PJ, Rogers SL, Friedhoff LT (1998). Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 46(Suppl 1): 13-18.
26. Tsukada H, Nishiyama S, Fukumoto D, Ohba H, Sato K, Kakiuchi T (2004). Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: functional imaging of the conscious monkey brain using animal PET in combination with microdialysis. Synapse 52: 1-10.
27. Veng PP (1977). Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J Pharmacokinet Biopharm 5: 513-531.
28. Yamanishi Y (1990). Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: comparison with other inhibitors. In: Nagatsu T, Fisher A, Yoshida M (eds). Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases. Plenum Press: London. pp 409-413.